Form 4: Fennec Pharma Director Sells Shares Under 10b5-1 Plan

Fennec Pharmaceuticals Director Rosty Raykov sold 10,000 common shares at $9.78 per share on October 6, 2025, under a pre-arranged 10b5-1 plan.

Summary

• Rosty Raykov, a Director of FENNEC PHARMACEUTICALS INC. (FENC), reported a transaction.
• The transaction involved the sale of 10,000 common shares.
• The shares were sold at a price of $9.78 per share.
• The transaction occurred on October 6, 2025.
• Following this sale, Rosty Raykov beneficially owns 82,501 common shares directly.
• The sale was executed pursuant to a Rule 10b5-1 trading plan established on August 23, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, it was conducted under a pre-arranged 10b5-1 plan, which typically indicates a planned financial management strategy rather than a reaction to new, non-public information about the company's prospects.

Negatives

• A director reduced their direct ownership in the company by selling 10,000 common shares.

Industry Context

This filing details a routine insider transaction for Fennec Pharmaceuticals, specifically a director's sale of shares. Such transactions are common across the biotechnology and pharmaceutical industry, often occurring under pre-arranged 10b5-1 plans to manage personal finances without implying a change in company outlook.

Stakeholder Impact

• Shareholders may note a director's reduction in direct shareholding, though the 10b5-1 plan mitigates concerns about discretionary selling.

Key Dates

Keywords

Fennec Pharmaceuticals, FENC, Rosty Raykov, Insider Transaction, Form 4, Share Sale, Director, 10b5-1 Plan